FOXO4-DRI is a senolytic peptide developed at Erasmus University Medical Center by de Keizer et al
Peptides are sensitive to temperature fluctuations, so place the vial in a consistent spot rather than in the door where temperatures swing with each opening
Upon contact with the skin, the serum greets you with an optimally viscous, silky texture that glides across the surface without leaving any stickiness, only a subtle, velvety softness
For users meaningfully lighter or cardiovascularly more responsive than the trial cohort low BMI, sub-160 lb, lean/recomposition-focused, older, or dose-sensitive the entry point drops to 0.3 mg
This tripeptide, just three amino acids (lysine-proline-valine), packs an outsized punch against the inflammatory machinery that drives allergic reactions